Differences in clinical features between small fiber and sensitive large fiber neuropathies in Sjögren's syndrome.


Journal

European journal of internal medicine
ISSN: 1879-0828
Titre abrégé: Eur J Intern Med
Pays: Netherlands
ID NLM: 9003220

Informations de publication

Date de publication:
09 2020
Historique:
received: 02 12 2019
accepted: 03 05 2020
pubmed: 31 5 2020
medline: 16 2 2021
entrez: 31 5 2020
Statut: ppublish

Résumé

To distinguish large (LFN) and small fiber neuropathies (SFN) in Sjögren's syndrome (SS) requires electroneuromyography (EMG) first, but this is time-consuming and has sometimes a limited accessibility, which can lead to a diagnostic delay. We aimed to identify clinical features that could distinguish SFN from sensitive LFN in SS. The study included patients with SS who were monitored in the internal medicine and neurology departments at Angers University Hospital between 2010 and 2016, and who were tested for suspected peripheral neuropathy. Patients with clinical motor involvement were excluded. LFN diagnosis was based on EMG. SFN diagnosis was based on intraepidermal nerve fiber density on skin biopsies in patients with no abnormality on EMG. LFN and SFN were diagnosed respectively in 22 (6.9%) and 17 (5.4%) patients among 317 patients with SS. Prevalence of anti-SSA antibodies was lower in the SFN group compared to the LFN group (p=0.002). The types of paresthesia did not differ between the 2 groups. After adjustment for age and sex, SFN was associated with dysautonomia (p=0.01, OR 8.4 [CI 95%: 1.7-42.4]) and without length-dependent topography (p=0.03, OR 0.2 [0.04-0.8] in comparison with the LFN group. An association of non-length-dependent pattern and dysautonomia seems to predict the absence of LFN in SS and encourages the search for SFN. In contrary, patients with length-dependent involvement and without dysautonomia should be prioritized for EMG.

Sections du résumé

BACKGROUND
To distinguish large (LFN) and small fiber neuropathies (SFN) in Sjögren's syndrome (SS) requires electroneuromyography (EMG) first, but this is time-consuming and has sometimes a limited accessibility, which can lead to a diagnostic delay. We aimed to identify clinical features that could distinguish SFN from sensitive LFN in SS.
METHODS
The study included patients with SS who were monitored in the internal medicine and neurology departments at Angers University Hospital between 2010 and 2016, and who were tested for suspected peripheral neuropathy. Patients with clinical motor involvement were excluded. LFN diagnosis was based on EMG. SFN diagnosis was based on intraepidermal nerve fiber density on skin biopsies in patients with no abnormality on EMG.
RESULTS
LFN and SFN were diagnosed respectively in 22 (6.9%) and 17 (5.4%) patients among 317 patients with SS. Prevalence of anti-SSA antibodies was lower in the SFN group compared to the LFN group (p=0.002). The types of paresthesia did not differ between the 2 groups. After adjustment for age and sex, SFN was associated with dysautonomia (p=0.01, OR 8.4 [CI 95%: 1.7-42.4]) and without length-dependent topography (p=0.03, OR 0.2 [0.04-0.8] in comparison with the LFN group.
CONCLUSIONS
An association of non-length-dependent pattern and dysautonomia seems to predict the absence of LFN in SS and encourages the search for SFN. In contrary, patients with length-dependent involvement and without dysautonomia should be prioritized for EMG.

Identifiants

pubmed: 32471733
pii: S0953-6205(20)30189-8
doi: 10.1016/j.ejim.2020.05.004
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

58-62

Informations de copyright

Copyright © 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

Carole Lacout (C)

Department of Internal Medicine, University Hospital, Angers, 49000, France. Electronic address: carolacout@wanadoo.fr.

Julien Cassereau (J)

Department of Neurology, Referral center for neuromuscular diseases, University Hospital, Angers, 49000, France. Electronic address: JuCassereau@chu-angers.fr.

Pierre Lozac'h (P)

Department of Internal Medicine, University Hospital, Angers, 49000, France. Electronic address: pierre.lozac@gmail.com.

Aline Gury (A)

Department of Internal Medicine, University Hospital, Angers, 49000, France. Electronic address: aline.gury@gmail.com.

Alaa Ghali (A)

Department of Internal Medicine, University Hospital, Angers, 49000, France. Electronic address: alghali@chu-angers.fr.

Christian Lavigne (C)

Department of Internal Medicine, University Hospital, Angers, 49000, France. Electronic address: chlavigne@chu-angers.fr.

Franck Letournel (F)

Department of Neurobiology and Neuropathology, University Hospital, Angers, 49000, France. Electronic address: franck.letournel@univ-angers.fr.

Geoffrey Urbanski (G)

Department of Internal Medicine, University Hospital, Angers, 49000, France. Electronic address: urbanskigeoffrey@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH